Literature DB >> 11895923

Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.

Anjali K Gupta1, W Gillies McKenna, Charles N Weber, Michael D Feldman, Jeffrey D Goldsmith, Rosemarie Mick, Mitchell Machtay, David I Rosenthal, Vincent J Bakanauskas, George J Cerniglia, Eric J Bernhard, Randal S Weber, Ruth J Muschel.   

Abstract

PURPOSE: Locoregional recurrence is the dominant form of treatment failure in head and neck (H&amp;N) cancer. The epidermal growth factor receptor (EGFR) is frequently amplified in this disease (<or=80%) and can lead to activation of phosphatidylinositol-3-kinase (PI3K), both directly and indirectly through Ras. We have shown previously that radioresistance could be conferred via the Ras-PI3K pathway. Here we investigate the contribution of EGFR to this pathway and its impact on treatment outcome. EXPERIMENTAL
DESIGN: In a series of 38 H&amp;N cancer patients, overexpression of EGFR by immunohistochemical staining was assessed. PI3K signaling was evaluated by staining for phosphorylated Akt (P-Akt), a downstream target of PI3K. Both EGFR and P-Akt were then related to outcome. Radiation survival was determined in the SQ20B cell line, a radioresistant squamous cell line derived from a recurrent laryngeal cancer, after pharmacological blockade of EGFR with Iressa, of Ras by the FTI L744,832, or of PI3K by LY294002.
RESULTS: A significant association was found between P-Akt staining and local control in the patient series. Two-year local control was 100% for patients staining 0-1+ for P-Akt as compared with 70.6% for patients staining 2-3+ (P = 0.04). In our series of 38 H&amp;N cancers, 30 (78.9%) of the specimens were strongly (3+) positive for EGFR, whereas 25 (65.8%) were moderately to strongly (2-3+) positive for P-Akt. Pharmacologically inhibiting EGFR, Ras, and PI3K led to radiosensitization of SQ20B cells.
CONCLUSIONS: Evaluation of PI3K activation by Akt phosphorylation might be a prognostic marker for response to therapy, and PI3K could be a useful target for therapy. These results also suggest that signaling from EGFR to PI3K can lead to radioresistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895923

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  103 in total

1.  Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.

Authors:  Andrew J Leiker; William DeGraff; Rajani Choudhuri; Anastasia L Sowers; Angela Thetford; John A Cook; Carter Van Waes; James B Mitchell
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  Signaling pathways in NSCLC as a predictor of outcome and response to therapy.

Authors:  Anjali K Gupta; Daniel E Soto; Michael D Feldman; Jeffrey D Goldsmith; Rosemarie Mick; Stephen M Hahn; Mitchell Machtay; Ruth J Muschel; W Gillies McKenna
Journal:  Lung       Date:  2004       Impact factor: 2.584

3.  Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo.

Authors:  Daisuke Sano; Jacob M Berlin; Tam T Pham; Daniela C Marcano; David R Valdecanas; Ge Zhou; Luka Milas; Jeffrey N Myers; James M Tour
Journal:  ACS Nano       Date:  2012-02-16       Impact factor: 15.881

Review 4.  Dysregulated molecular networks in head and neck carcinogenesis.

Authors:  Alfredo A Molinolo; Panomwat Amornphimoltham; Cristiane H Squarize; Rogerio M Castilho; Vyomesh Patel; J Silvio Gutkind
Journal:  Oral Oncol       Date:  2008-09-19       Impact factor: 5.337

5.  Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma.

Authors:  Priya Koppikar; Seung-Ho Choi; Ann Marie Egloff; Quan Cai; Shinsuke Suzuki; Maria Freilino; Hiroshi Nozawa; Sufi M Thomas; William E Gooding; Jill M Siegfried; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

6.  Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors.

Authors:  Xiaofei Chen; Liang Liu; Jade Mims; Elizabeth C Punska; Kristin E Williams; Weiling Zhao; Kathleen F Arcaro; Allen W Tsang; Xiaobo Zhou; Cristina M Furdui
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

7.  Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Authors:  Jacob I Tower; Mark W Lingen; Tanguy Y Seiwert; Alexander Langerman
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

8.  Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.

Authors:  Arron Sikka; Manjinder Kaur; Chapla Agarwal; Gagan Deep; Rajesh Agarwal
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

9.  The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

Authors:  Joon-Yong Chung; Seung-Mo Hong; Byeong Yeob Choi; Hyungjun Cho; Eunsil Yu; Stephen M Hewitt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 10.  Inhibiting PI3K as a therapeutic strategy against cancer.

Authors:  Luis Paz-Ares; Carmen Blanco-Aparicio; Rocío García-Carbonero; Amancio Carnero
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.